Treating unstable angina with detoxifying and blood-activating formulae: A randomized controlled trial.
Wu M, Yang S, Liu G, Gu C, Ren P, Zhao R, Zhao Y, Xing Y, Liu L, Liang J.
Wu M, et al.
J Ethnopharmacol. 2021 Dec 5;281:114530. doi: 10.1016/j.jep.2021.114530. Epub 2021 Aug 17.
J Ethnopharmacol. 2021.
PMID: 34416295
Clinical Trial.
The primary endpoint was the frequency of weekly angina pectoris attacks before and after treatment. The secondary endpoints, also observed before and after treatment, included blood glucose, blood lipids, high-sensitivity C-reactive protein (hs-CRP), tumor necrosis …
The primary endpoint was the frequency of weekly angina pectoris attacks before and after treatment. The secondary endpoints, …